Takeda Pharmaceutical (NYSE:TAK) CEO Sells $1,523,439.00 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) CEO Julie So-Young Kim sold 89,090 shares of Takeda Pharmaceutical stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $1,523,439.00. Following the sale, the chief executive officer owned 391,489 shares in the company, valued at $6,694,461.90. The trade was a 18.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

TAK traded down $0.06 during trading on Wednesday, hitting $17.42. 2,004,364 shares of the company traded hands, compared to its average volume of 4,402,927. Takeda Pharmaceutical Co. has a one year low of $12.99 and a one year high of $18.90. The stock’s fifty day moving average is $16.49 and its 200 day moving average is $17.13. The company has a quick ratio of 0.62, a current ratio of 1.14 and a debt-to-equity ratio of 0.58. The firm has a market cap of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $0.56 EPS for the quarter. The business had revenue of $6.90 billion for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. As a group, equities analysts predict that Takeda Pharmaceutical Co. will post 3.01 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Weiss Ratings cut shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Institutional Trading of Takeda Pharmaceutical

A number of institutional investors have recently modified their holdings of TAK. Private Trust Co. NA grew its stake in Takeda Pharmaceutical by 84.7% in the 4th quarter. Private Trust Co. NA now owns 1,707 shares of the company’s stock valued at $27,000 after buying an additional 783 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Takeda Pharmaceutical by 192.2% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,560 shares of the company’s stock worth $40,000 after acquiring an additional 1,684 shares in the last quarter. SHP Wealth Management bought a new position in shares of Takeda Pharmaceutical in the fourth quarter worth $42,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Takeda Pharmaceutical by 313.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,070 shares of the company’s stock worth $48,000 after acquiring an additional 2,328 shares during the period. Finally, Northwestern Mutual Wealth Management Co. grew its position in shares of Takeda Pharmaceutical by 56.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 3,586 shares of the company’s stock valued at $55,000 after purchasing an additional 1,292 shares in the last quarter. 9.17% of the stock is currently owned by hedge funds and other institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.